Furthermore, comparing T cell activation in the spleens of the anti-PD-1 monotherapy and the Combination + anti-PD-1 group suggests that local tumor intervention also promotes systemic immune activation (Fig. 3k). This evidence concerns the gene PDCD1 and neoplasm.